Cox-2 selective nonsteroidal anti-inflammatory drugs

Over the years since 2002 I have had a hip replacement (AVN after hit by a car) several years later the other hip was replaced due to OA, 2012 was my first knee replacement and 2014 my second (both done at NE Baptist hospital in Boston) Significant pain pre and post replacements. Relief was obtained with Vioxx,
(until off the market) then ibuprofen, tylenol PM at night. Opioids prescribed post op but not used after 2-3 weeks home. I was never told not to take ansaids nor that my healing was less then what was expected. I returned to my job as homecare case manager after all surgeries within 12 weeks, lots of physical activity required. Always x strength tylenol suggested (never effective for me)
! month ago I underwent back surgery . Discharged on neurontin and roxicet and of course x strength tylenol. Pain has been hard to control (developed sciatic pain especially at night) Calls to MD resulted in increased dose of both neurontin and opioids. Also using ice and topical ointments with some short term decrease in pain. While using cane for balance I injured my rotator cuff L shouider. I was told by my surgeon absolutely no ansaids. Finding this incredibly difficult and started looking for articles and information on this as it has such an impact on pain management and recovery. Ambulation and sleep are
difficult as are ability to stay positive. I found this article helpful and hope there is indeed more research going on. Thank you for this site Pam

The safety of non-selective non-steroidal anti-inflammatory drugs (non-selective NSAIDs) has been evaluated by the Medicines Adverse Reactions Committee (MARC).  Non-selective NSAIDs do not differentiate between COX-1 and COX-2 in their inhibitory action, and are a separate class of drug to the COX-2 inhibitors.  As part of their evaluation, the MARC reviewed adverse reaction reports received by the Centre for Adverse Reactions Monitoring (CARM) and the WHO (Vigibase), together with recently published literature and international regulatory activity.

This was a retrospective case-control study based on insurance claims, with chart review to confirm cases. The base population consisted of million adult users of celecoxib, diclofenac, ibuprofen, naproxen, rofecoxib, or valdecoxib who were covered by commercial health insurance in the United States from 1999-2003. For 790 persons hospitalized for PUBP and 7887 controls, most recent NSAID/COX-2 use and a variety of medical and pharmacy risk factors were ascertained from the insurance files and analyzed by conditional logistic regression. The main outcome measure was the odds ratio (OR) associated with use of each drug by comparison to naproxen, and in successive intervals after last dispensing.

The adverse drug reaction profile observed in pediatric clinical trials (children and adolescents) was consistent with the adverse drug reaction profile observed in adult clinical trials. The specific adverse drug reactions observed in adult patients can be expected to be observed in pediatric patients (children and adolescents) [see Adverse Reactions Occurring At An Incidence Of 2% Or More Among CYMBALTA-Treated Patients In Adult Placebo-Controlled Trials ]. The most common (≥5% and twice placebo) adverse reactions observed in pediatric clinical trials include: nausea, diarrhea, decreased weight, and dizziness.

Cox-2 selective nonsteroidal anti-inflammatory drugs

cox-2 selective nonsteroidal anti-inflammatory drugs

The adverse drug reaction profile observed in pediatric clinical trials (children and adolescents) was consistent with the adverse drug reaction profile observed in adult clinical trials. The specific adverse drug reactions observed in adult patients can be expected to be observed in pediatric patients (children and adolescents) [see Adverse Reactions Occurring At An Incidence Of 2% Or More Among CYMBALTA-Treated Patients In Adult Placebo-Controlled Trials ]. The most common (≥5% and twice placebo) adverse reactions observed in pediatric clinical trials include: nausea, diarrhea, decreased weight, and dizziness.

Media:

cox-2 selective nonsteroidal anti-inflammatory drugscox-2 selective nonsteroidal anti-inflammatory drugscox-2 selective nonsteroidal anti-inflammatory drugscox-2 selective nonsteroidal anti-inflammatory drugscox-2 selective nonsteroidal anti-inflammatory drugs